Safety and Efficacy of Combination Therapy of Upadacitinib and Biologic Agents for Treatment-Resistant Psoriasis and Psoriatic Arthritis
Main Article Content
Keywords
upadacitinib, biologics, psoriatic arthritis, psoriasis
Abstract
Importance: Although there are many available treatments for psoriasis and psoriatic arthritis (PsA), there are patients resistant to standard conventional therapy. For these patients, combination therapy of biologic agents and upadacitinib may be a viable alternative option; however, there is limited data on concomitant usage.
Objective: To evaluate the safety and efficacy of combination therapy of upadacitinib and biologic agents for the treatment of refractory psoriasis and psoriatic arthritis.
Design: We report the results of a retrospective chart review of 3 patients in a single practice treated with a combination of upadacitinib and biologics for psoriasis and PsA. The risks, benefits, and safety warnings of combination therapy of upadacitinib and biologic agents were discussed before initiation. After shared decision-making with the provider, patients were placed on a trial of combination therapy.
Results: All three patients, previously refractory to monotherapy, experienced significant improvement of their symptoms while on combination therapy. No adverse reactions (malignancy, cardiovascular events, venous thromboembolism) occurred during treatment. However, one patient experienced a shingles outbreak and diverticulitis while on combination treatment. Further studies are needed to determine long-term efficacy with a larger sample size.
References
2. Ocampo D, V., & Gladman, D. (2019). Psoriatic arthritis. F1000Research, 8, F1000 Faculty Rev-1665. https://doi.org/10.12688/f1000research.19144.1
3. Lee, B. W., & Moon, S. J. (2023). Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment. International journal of molecular sciences, 24(14), 11662. https://doi.org/10.3390/ijms241411662
4. Watson, S. (2022, June 17). Treatment Options for Psoriatic Arthritis. Arthritis Foundation. https://www.arthritis.org/health-wellness/treatment/treatment-plan/disease-management/treatment-options-for-psoriatic-arthritis
5. Gerriets, V., Goyal, A., & Khaddour, K. (2023). Tumor Necrosis Factor Inhibitors. In StatPearls. StatPearls Publishing.
6. Miller, J., Puravath, A. P., & Orbai, A. M. (2021). Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection. Journal of inflammation research, 14, 6975–6991. https://doi.org/10.2147/JIR.S229752
7. McInnes, I. B., Sawyer, L. M., Markus, K., LeReun, C., Sabry-Grant, C., & Helliwell, P. S. (2022). Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD open, 8(1), e002074. https://doi.org/10.1136/rmdopen-2021-002074
8. Bai, F., Li, G. G., Liu, Q., Niu, X., Li, R., & Ma, H. (2019). Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Journal of immunology research, 2019, 2546161. https://doi.org/10.1155/2019/2546161
9. Deng, Z., Wang, S., Wu, C., & Wang, C. (2023). IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Frontiers in pharmacology, 14, 1124628. https://doi.org/10.3389/fphar.2023.1124628
10. Kristensen, L. E., Keiserman, M., Papp, K., McCasland, L., White, D., Lu, W., Wang, Z., Soliman, A. M., Eldred, A., Barcomb, L., & Behrens, F. (2022). Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Annals of the rheumatic diseases, 81(2), 225–231. https://doi.org/10.1136/annrheumdis-2021-221019
11. Mease, P. J., Lertratanakul, A., Anderson, J. K., Papp, K., Van den Bosch, F., Tsuji, S., Dokoupilova, E., Keiserman, M., Wang, X., Zhong, S., McCaskill, R. M., Zueger, P., Pangan, A. L., & Tillett, W. (2021). Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Annals of the rheumatic diseases, 80(3), 312–320. https://doi.org/10.1136/annrheumdis-2020-218870
12. McInnes, I. B., Kato, K., Magrey, M., Merola, J. F., Kishimoto, M., Haaland, D., Chen, L., Duan, Y., Liu, J., Lippe, R., & Wung, P. (2023). Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. Rheumatology and therapy, 10(1), 275–292. https://doi.org/10.1007/s40744-022-00499-w
13. RINVOQ® (upadacitinib) for active Psoriatic Arthritis (PsA). RINVOQ® (upadacitinib). (n.d.). https://www.rinvoq.com/psoriatic-arthritis
14. Burmester, G. R., Winthrop, K., Blanco, R., Nash, P., Goupille, P., Azevedo, V. F., Salvarani, C., Rubbert-Roth, A., Lesser, E., Lippe, R., Lertratanakul, A., Mccaskill, R. M., Liu, J., & Ruderman, E. M. (2022). Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatology and therapy, 9(2), 521–539. https://doi.org/10.1007/s40744-021-00410-z
15. Mazhar, F., Krantz, Å., Schalin, L., Lysell, J., & Carrero, J. J. (2023). Occurrence of adverse events associated with the initiation of methotrexate and biologics for the treatment of psoriasis in routine clinical practice. The Journal of dermatological treatment, 34(1), 2215354. https://doi.org/10.1080/09546634.2023.2215354
16. Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017). JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs, 77(5), 521–546. https://doi.org/10.1007/s40265-017-0701-9
17. Chen, M., & Dai, S. M. (2020). A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chinese medical journal, 133(8), 959–967. https://doi.org/10.1097/CM9.0000000000000711
18. Ogata, A., Kumanogoh, A., & Tanaka, T. (2012). Pathological role of interleukin-6 in psoriatic arthritis. Arthritis, 2012, 713618. https://doi.org/10.1155/2012/713618
19. Mizutani, H., Ohmoto, Y., Mizutani, T., Murata, M., & Shimizu, M. (1997). Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. Journal of dermatological science, 14(2), 145–153. https://doi.org/10.1016/s0923-1811(96)00562-2
20. Przepiera-Będzak, H., Fischer, K., & Brzosko, M. (2015). Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Mediators of inflammation, 2015, 785705. https://doi.org/10.1155/2015/785705
21. Cai F, Sornasse T, Ruzek M, et al. OP0024 DIFFERENTIATION BETWEEN IL-6 AND IL-17 PATHWAY INHIBITION IN RELATIONSHIP WITH CLINICAL OUTCOMES IN NON-BIOLOGICAL DMARD-IR AND BIOLOGICAL DMARD-IR PSORIATIC ARTHRITIS PATIENTS TREATED WITH UPADACITINIB IN SELECT-PsA 1 AND SELECT-PsA 2 STUDIES. Annals of the Rheumatic Diseases 2022; 81:17-18.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.